Published in J Exp Med on August 02, 1999
Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med (2007) 3.15
Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci U S A (2000) 1.91
Molecular profile of synovial fibroblasts in rheumatoid arthritis depends on the stage of proliferation. Arthritis Res (2002) 1.19
The protease complex consisting of dipeptidyl peptidase IV and seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices. Cancer Res (2006) 1.15
Transmigration of melanoma cells through the blood-brain barrier: role of endothelial tight junctions and melanoma-released serine proteases. PLoS One (2011) 1.11
Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer. Br J Cancer (2000) 1.08
Potential of soluble CD26 as a serum marker for colorectal cancer detection. World J Clin Oncol (2011) 1.04
Expression and activity profiles of DPP IV/CD26 and NEP/CD10 glycoproteins in the human renal cancer are tumor-type dependent. BMC Cancer (2010) 0.95
5-Aza-2'-deoxycytidine induced growth inhibition of leukemia cells through modulating endogenous cholesterol biosynthesis. Mol Cell Proteomics (2012) 0.94
Suppression of neuroblastoma growth by dipeptidyl peptidase IV: relevance of chemokine regulation and caspase activation. Oncogene (2008) 0.92
Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells. Clin Exp Metastasis (2000) 0.89
Adenosine down-regulates the surface expression of dipeptidyl peptidase IV on HT-29 human colorectal carcinoma cells: implications for cancer cell behavior. Am J Pathol (2004) 0.88
CD26/dipeptidyl peptidase IV in context. The different roles of a multifunctional ectoenzyme in malignant transformation. J Exp Med (1999) 0.86
The Potential Role of MT and Vimentin Immunoreactivity in the Remodeling of the Microenvironment of Parotid Adenocarcinoma. Cancer Microenviron (2010) 0.86
Inhibition of circulating dipeptidyl peptidase 4 activity in patients with metastatic prostate cancer. Mol Cell Proteomics (2014) 0.82
The Long Noncoding RNA SPRIGHTLY Regulates Cell Proliferation in Primary Human Melanocytes. J Invest Dermatol (2016) 0.81
Circulating FGF21 proteolytic processing mediated by fibroblast activation protein. Biochem J (2015) 0.80
Lymphatic-specific expression of dipeptidyl peptidase IV and its dual role in lymphatic endothelial function. Exp Cell Res (2008) 0.80
The dietary flavonoid apigenin enhances the activities of the anti-metastatic protein CD26 on human colon carcinoma cells. Clin Exp Metastasis (2011) 0.78
Differential Expression and Enzymatic Activity of DPPIV/CD26 Affects Migration Ability of Cervical Carcinoma Cells. PLoS One (2015) 0.78
Impact of fibroblast activation protein on osteosarcoma cell lines in vitro. Oncol Lett (2014) 0.77
Chemotherapeutic agents attenuate CXCL12-mediated migration of colon cancer cells by selecting for CXCR4-negative cells and increasing peptidase CD26. BMC Cancer (2015) 0.77
Dipeptidyl peptidase 10, a novel prognostic marker in colorectal cancer. Yonsei Med J (2013) 0.77
Serum activity of DPPIV and its expression on lymphocytes in patients with melanoma and in people with vitiligo. BMC Immunol (2012) 0.77
Interspecies differences in membrane-associated protease activities of thyrocytes and their relevance for thyroid cancer studies. J Exp Clin Cancer Res (2012) 0.76
Low expression of angiotensinogen and dipeptidyl peptidase 1 in saliva of patients with proliferative verrucous leukoplakia. World J Clin Cases (2016) 0.75
Downregulation of Signaling-active IGF-1 by Dipeptidyl Peptidase IV (DPP-IV). Int J Biomed Sci (2010) 0.75
Expression of GLP-1 receptor and CD26 in human thyroid C-cells: The association of thyroid C-cell tumorigenesis with incretin-based medicine. Oncol Lett (2017) 0.75
Co-expression of the homologous proteases fibroblast activation protein and dipeptidyl peptidase-IV in the adult human Langerhans islets. Histochem Cell Biol (2014) 0.75
Regulation of Dipeptidyl Peptidase IV in the Post-stroke Rat Brain and In Vitro Ischemia: Implications for Chemokine-Mediated Neural Progenitor Cell Migration and Angiogenesis. Mol Neurobiol (2016) 0.75
Transcriptional activation by tetracyclines in mammalian cells. Science (1995) 13.90
Autocrine secretion and malignant transformation of cells. N Engl J Med (1980) 7.49
ECM and cell surface proteolysis: regulating cellular ecology. Cell (1997) 6.00
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med (1982) 3.27
Selective proliferation of normal human melanocytes in vitro in the presence of phorbol ester and cholera toxin. Proc Natl Acad Sci U S A (1982) 2.97
Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A (1990) 2.91
The structure and function of CD26 in the T-cell immune response. Immunol Rev (1998) 1.84
Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med (1998) 1.69
The thyroid hormone-induced tail resorption program during Xenopus laevis metamorphosis. Proc Natl Acad Sci U S A (1996) 1.68
Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med (1997) 1.67
Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells. J Exp Med (1987) 1.65
Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J Biol Chem (1998) 1.53
Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res (1993) 1.50
Differentiation antigens of melanocytes and melanoma: analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies. J Invest Dermatol (1988) 1.34
Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha. FEBS Lett (1998) 1.18
Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc Natl Acad Sci U S A (1998) 1.15
Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue. Prostate (1997) 1.14
A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase. J Exp Med (1993) 1.13
Metastatic but not primary melanoma cell lines grow in vitro independently of exogenous growth factors. Int J Cancer (1987) 1.11
Functional comparison of two human monocyte chemotactic protein-2 isoforms, role of the amino-terminal pyroglutamic acid and processing by CD26/dipeptidyl peptidase IV. Biochemistry (1998) 1.07
Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol (1997) 1.06
Purification and subunit structure of adenosine deaminase from human kidney. J Biol Chem (1977) 1.01
Cell surface antigens of human melanocytes and melanoma. Expression of adenosine deaminase binding protein is extinguished with melanocyte transformation. J Exp Med (1988) 1.00
Malignant transformation of human melanocytes: induction of a complete melanoma phenotype and genotype. Oncogene (1992) 1.00
Characterization of the adenosine deaminase-adenosine deaminase complexing protein binding reaction. J Biol Chem (1990) 0.93
bcl-2 protein expression in melanocytic neoplasms of the skin. Mod Pathol (1995) 0.91
Accelerated disappearance of melanocytes in bcl-2-deficient mice. Cancer Res (1996) 0.90
Adenosine deaminase complexing protein (ADCP) immunoreactivity in colorectal adenocarcinoma. Int J Cancer (1986) 0.89
Rapid chromatographic purification of dipeptidyl peptidase IV in human submaxillary gland. J Chromatogr (1980) 0.87
Adenosine deaminase complexing protein (ADCP) expression and metastatic potential in prostatic adenocarcinomas. J Pathol (1990) 0.86
Post-secretory processing of regulatory peptides: the pancreatic polypeptide family as a model example. Biochimie (1994) 0.84
Adenosine deaminase complexing protein in cancer studies. Anticancer Res (1987) 0.83
The cytoplasmic tail of the mouse brown locus product determines intracellular stability and export from the endoplasmic reticulum. J Invest Dermatol (1998) 0.83
Surface antigens of human melanoma cells cultured in serum-free medium: induction of expression of major histocompatibility complex class II antigens. Cancer Res (1988) 0.81
Localization of an adenosine deaminase-binding protein in human kidney. J Lab Clin Med (1978) 0.79
Distribution of adenosine deaminase binding protein in normal and malignant tissues of the gastrointestinal tract studied by monoclonal antibodies. J Surg Oncol (1993) 0.79
Adenosine deaminase complexing protein (ADCP): a transformation sensitive protein with potentials of a cancer marker. Anticancer Res (1983) 0.78
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol (1999) 5.95
The tumor autocrine motility factor receptor, gp78, is a ubiquitin protein ligase implicated in degradation from the endoplasmic reticulum. Proc Natl Acad Sci U S A (2001) 3.39
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med (1982) 3.27
Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens. J Exp Med (1981) 2.53
The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med (1990) 2.44
Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med (2000) 2.25
Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med (1999) 2.15
Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A (1985) 2.14
Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity? Nature (1984) 2.14
Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med (1995) 2.13
Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest (1998) 2.02
Induction of pigmentation in mouse fibroblasts by expression of human tyrosinase cDNA. J Exp Med (1989) 1.98
Heteroclitic immunization induces tumor immunity. J Exp Med (1998) 1.92
Serological survey of normal humans for natural antibody to cell surface antigens of melanoma. Proc Natl Acad Sci U S A (1980) 1.86
Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci U S A (1996) 1.85
Surface antigens of melanoma and melanocytes. Specificity of induction of Ia antigens by human gamma-interferon. J Exp Med (1984) 1.81
Intracellular sorting and targeting of melanosomal membrane proteins: identification of signals for sorting of the human brown locus protein, gp75. J Cell Biol (1995) 1.76
PANNOTATOR: an automated tool for annotation of pan-genomes. Genet Mol Res (2013) 1.74
Ras oncogene point mutation: an infrequent event in bronchioloalveolar cancer. J Thorac Cardiovasc Surg (1992) 1.72
Generation of human monoclonal antibodies reactive with cellular antigens. Proc Natl Acad Sci U S A (1983) 1.71
Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med (1998) 1.69
Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells. J Exp Med (1987) 1.65
Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial. Proc Natl Acad Sci U S A (2001) 1.63
Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine (2005) 1.59
Cell surface antigens of human astrocytoma defined by mouse monoclonal antibodies: identification of astrocytoma subsets. Proc Natl Acad Sci U S A (1982) 1.59
Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci U S A (1992) 1.58
A lineage-restricted and divergent beta-tubulin isoform is essential for the biogenesis, structure and function of blood platelets. Curr Biol (2001) 1.54
Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer (1993) 1.52
Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res (1993) 1.50
Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma. J Exp Med (1983) 1.48
Class 1 (unique) tumor antigens of human melanoma. Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody. J Exp Med (1984) 1.48
Interruption of classic CD40L-CD40 signalling but not of the novel CD40L-Mac-1 interaction limits arterial neointima formation in mice. Thromb Haemost (2014) 1.41
Loss of polymorphic restriction fragments in malignant melanoma: implications for tumor heterogeneity. Proc Natl Acad Sci U S A (1985) 1.39
PTPROt: an alternatively spliced and developmentally regulated B-lymphoid phosphatase that promotes G0/G1 arrest. Blood (1999) 1.36
Evaluation of Elispot assays: influence of method and operator on variability of results. J Immunol Methods (2004) 1.36
Differentiation antigens of melanocytes and melanoma: analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies. J Invest Dermatol (1988) 1.34
Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int J Cancer (1993) 1.31
Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70. Proc Natl Acad Sci U S A (2000) 1.26
Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues. Cancer Res (1985) 1.24
Biochemical analysis of two cell surface glycoprotein complexes, very common antigen 1 and very common antigen 2. Relationship to very late activation T cell antigens. J Biol Chem (1987) 1.23
Evidence against Ha-ras-1 involvement in sporadic and familial melanoma. Nature (1987) 1.21
Human cutaneous mast cells express basic fibroblast growth factor. Lab Invest (1995) 1.21
Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression. Am J Pathol (1994) 1.19
Molecular cloning of the human kidney differentiation antigen gp160: human aminopeptidase A. Proc Natl Acad Sci U S A (1993) 1.16
A melanosomal membrane protein is a cell surface target for melanoma therapy. Clin Cancer Res (1996) 1.15
Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery (2000) 1.15
The impact of Nepal's national incentive programme to promote safe delivery in the district of Makwanpur. Adv Health Econ Health Serv Res (2009) 1.14
Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue. Prostate (1997) 1.14
A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase. J Exp Med (1993) 1.13
A role for a melanosome transport signal in accessing the MHC class II presentation pathway and in eliciting CD4+ T cell responses. J Immunol (1999) 1.12
Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas. Cancer (1992) 1.12
Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA. J Clin Invest (1993) 1.11
Characterization of cell lines established from human gastric-esophageal adenocarcinomas. Biologic phenotype and invasion potential. Cancer (1993) 1.10
Mutations and defective expression of the WAF1 p21 tumour-suppressor gene in malignant melanomas. Melanoma Res (1995) 1.10
Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. Int J Cancer (2000) 1.10
Definition of tumor antigens suitable for vaccine construction. Semin Cancer Biol (1995) 1.10
Loss of heterozygosity at autosomal and X-linked loci during tumor progression in a patient with melanoma. Cancer Res (1987) 1.09
Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin. Clin Cancer Res (1999) 1.08
The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int J Cancer (1995) 1.07
Mutational analysis of the human p53 gene in malignant melanoma. Pigment Cell Res (1991) 1.07
Elevated expression of protein tyrosine kinase c-Yes, but not c-Src, in human malignant melanoma. Oncogene (1993) 1.07
Pulmonary functions in Indian sportsmen playing different sports. Indian J Physiol Pharmacol (1998) 1.07
Monoclonal antibody therapies-a 'constant' threat to cancer. Nat Med (2000) 1.06
Induction of human tenascin (neuronectin) by growth factors and cytokines: cell type-specific signals and signalling pathways. J Cell Sci (1994) 1.06
Chemotherapy and P-glycoprotein expression in chondrosarcoma. J Orthop Res (1998) 1.05
Defining the invasive phenotype of proximal gastric cancer cells. Cancer (1994) 1.04
Increased facilitated transport of dehydroascorbic acid without changes in sodium-dependent ascorbate transport in human melanoma cells. Cancer Res (1997) 1.04
Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside. Melanoma Res (1997) 1.03
Biosynthesis and intracellular movement of the melanosomal membrane glycoprotein gp75, the human b (brown) locus product. Exp Cell Res (1991) 1.03
Sorting and secretion of a melanosome membrane protein, gp75/TRP1. J Invest Dermatol (1997) 1.03
Assignment of the human TYRP (brown) locus to chromosome region 9p23 by nonradioactive in situ hybridization. Genomics (1992) 1.03
Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection. Int J Cancer (1995) 1.01
In vitro expansion of Ag-specific T cells by HLA-A*0201-transfected K562 cells for immune monitoring. Cytotherapy (2006) 1.01
Malignant melanoma of the skin occurring during pregnancy. Cancer (1981) 1.01
Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst (1993) 1.01
Malignant transformation of human melanocytes: induction of a complete melanoma phenotype and genotype. Oncogene (1992) 1.00
Cell surface antigens of human melanocytes and melanoma. Expression of adenosine deaminase binding protein is extinguished with melanocyte transformation. J Exp Med (1988) 1.00
Protein kinase C: a novel target for inhibiting gastric cancer cell invasion. J Natl Cancer Inst (1993) 1.00
Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients. Clin Cancer Res (2000) 1.00
The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients. Eur J Cancer (2012) 0.98
Biochemical analysis of a 130,000 molecular weight glycoprotein on human melanoma cells. J Immunol (1983) 0.97
Specificity analysis of human monoclonal antibodies reactive with cell surface and intracellular antigens. Proc Natl Acad Sci U S A (1986) 0.97
Reactivity of autologous CD4+ T lymphocytes against human melanoma. Evidence for a shared melanoma antigen presented by HLA-DR15. J Immunol (1995) 0.97
Mutational analysis of human NRAS genes in malignant melanoma: rapid methods for oligonucleotide hybridization and manual and automated direct sequencing of products generated by the polymerase chain reaction. Genes Chromosomes Cancer (1990) 0.96
Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. J Clin Oncol (1988) 0.95
Antiproliferative and antitumor effects of alpha-interferon in renal cell carcinomas: correlation with the expression of a kidney-associated differentiation glycoprotein. Cancer Res (1990) 0.95
Infrequent point mutations of ras oncogenes in gastric cancers. Gastroenterology (1990) 0.95
Three human cell surface antigen systems determined by genes on chromosome 12. Somat Cell Mol Genet (1984) 0.95
Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity: implications for the clinical use of dendritic cells. J Immunol (2000) 0.95
Serological response of melanoma patients receiving melanoma cell vaccines. I. Autologous cultured melanoma cells. Int J Cancer (1982) 0.94
Class II histocompatibility antigen expression in human melanocytes transformed by Harvey murine sarcoma virus (Ha-MSV) and Kirsten MSV retroviruses. J Exp Med (1986) 0.94
Light chain variants of an IgG3 anti-GD3 monoclonal antibody and the relationship among avidity, effector functions, tumor targeting, and antitumor activity. Cancer Res (1990) 0.94
Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol (1995) 0.93
Establishment and characterization of two human myeloma cell lines secreting kappa light chains. Leukemia (1989) 0.93